Stanley Druckenmiller's RLAY Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 349,000 shares of Relay Therapeutics, Inc. (RLAY) worth $6.53 M, representing 0.13% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Stanley Druckenmiller has initiated a new position in RLAY, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's Relay Therapeutics (RLAY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Relay Therapeutics (RLAY) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +349,000 | New Buy | 349,000 | $18.71 |
Stanley Druckenmiller's Relay Therapeutics Investment FAQs
Stanley Druckenmiller first purchased Relay Therapeutics, Inc. (RLAY) in Q2 2026, acquiring 349,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held Relay Therapeutics, Inc. (RLAY) for 1 quarters since Q2 2026.
Stanley Druckenmiller's largest addition to Relay Therapeutics, Inc. (RLAY) was in Q2 2026, adding 349,000 shares worth $6.53 M.
According to the latest 13F filing for Q2 2026, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 349,000 shares of Relay Therapeutics, Inc. (RLAY), valued at approximately $6.53 M.
As of the Q2 2026 filing, Relay Therapeutics, Inc. (RLAY) represents approximately 0.13% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in Relay Therapeutics, Inc. (RLAY) was 349,000 shares, as reported at the end of Q2 2026.